Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,708.99
+23.560.88%
Number of Gainers:57
Number of Losers:39
Number of Flat:2
PE:- -
High:2,717.52
Open:2,685.39
Low:2,685.39
Close:2,685.43
Volume:1.14B
Turnover:222.75B
Market Cap:49.54T
Float Cap:46.10T

Loading ...

What the History of Electric Wires Can Teach Us About the Data Center Backlash

InvestorPlace
·
Sep 30

Premarket: Nasdaq Futures Slip 0.09% as Investors Await Micron Earnings

Deep News
·
Sep 30

Breaking: Jensen Huang Set to Take On Role at Tsinghua University

Deep News
·
Sep 30

Trane announces demonstration of 800-volt direct current chiller

TIPRANKS
·
Sep 30

Silo Pharma Unit QwikAgents Adds Nvidia Nemotron Model Support

Reuters
·
Sep 30

Silo Pharma’s Qwikagents Expands AI Agent Platform with Nvidia Model Support and New Runtime Flexibility

THOMSON REUTERS
·
Sep 30

Cummins Inc : UBS Cuts Target Price to $741 from $835

THOMSON REUTERS
·
Sep 30

AIxCrypto to change name to FF EAI Robotics Ecosystem

TIPRANKS
·
Sep 30

UBS Sticks to Its Hold Rating for Apple (AAPL)

TIPRANKS
·
Sep 30

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Sep 30

Skyworks Secures Regulatory Clearances for Qorvo Deal, Targets Oct. 5 Close

Reuters
·
Sep 30

Qorvo - Skyworks and Qorvo Expect to Close Mergers on or About October 5, 2026

THOMSON REUTERS
·
Sep 30

Press Release: Skyworks Receives All Necessary Clearances for Proposed Combination with Qorvo

Dow Jones
·
Sep 30

Micron Faces Earnings Test Tonight After 40% Stock Rebound: Net Income Expected to Surge Over 1000%, Market Focuses on Next Year's AI Capital Expenditure

Deep News
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

European Payments Groups Join Forces to Challenge US Dominance

Reuters
·
Sep 30